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The grade of histologic differentiation is one of the most impor-
tant prognostic factors in patients with endometrial carcinoma
and postoperative staging. The aim of this study was to inves-
tigate whether 16a-18F-fluoro-17b-estradiol (18F-FES) and
18F-FDG PET reflect clinicopathologic features in patients with
endometrial tumors. Methods: A total of 22 patients with endo-
metrial adenocarcinoma and 9 with endometrial hyperplasia
(mean age, 56.0 6 15.3 y) underwent 18F-FES PET for estrogen
receptor imaging and 18F-FDG PET. Regional values of tracer up-
take were evaluated using standardized uptake value (SUV) and
the SUV ratio of 18F-FDG to 18F-FES. The accuracy for predicting
tumor aggressiveness defined as high-risk carcinoma (Interna-
tional Federation of Gynecology and Obstetrics [FIGO] stage $
Ic or histologic grade $ 2), low-risk carcinoma (FIGO stage #
Ib and grade 1), and hyperplasia was compared for each PET pa-
rameter using receiver-operating-characteristic (ROC) analysis.
The diagnostic accuracy of MRI findings for clinical staging
was also compared. Results: Although the SUV for 18F-FDG
was significantly lower in endometrial hyperplasia than in carci-
noma, a significant difference between high-risk and low-risk
carcinoma was observed only in SUV for 18F-FES. High-risk car-
cinoma showed a significantly greater 18F-FDG–to–18F-FES ratio
(3.66 2.1) than did low-risk carcinoma (1.36 0.5, P, 0.01) and
hyperplasia (0.36 0.1, P, 0.005). Low-risk carcinoma showed a
significantly higher 18F-FDG–to–18F-FES ratio than hyperplasia
(P , 0.0001). In ROC analysis, the most accurate diagnostic
PET parameter for predicting high-risk and low-risk carcinoma
was the 18F-FDG–to–18F-FES ratio. The optimal 18F-FDG/18F-
FES cutoff value of 2.0, determined by ROC analysis, revealed
73% sensitivity, 100% specificity, and 86% accuracy, which
was better than the 77% accuracy for MRI. The 18F-FDG–
to–18F-FES ratio of 0.5 yielded a correct diagnosis for carcinoma
from hyperplasia with 100% accuracy. Conclusion: Endometrial
carcinoma reduces estrogen dependency with accelerated glu-
cose metabolism as it progresses to a higher stage or grade.
18F-FES and 18F-FDG PET studies provide a new index of the
18F-FDG–to–18F-FES ratio, which is considered the most infor-
mative index reflecting tumor aggressiveness. This index will
be useful for making noninvasive diagnoses and deciding the ap-
propriate therapeutic strategy for patients with endometrial car-
cinoma.
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Endometrial carcinoma is a highly prevalent gyneco-
logic malignancy and one of the most common female
malignant tumors in Western countries, including the
United States, and in Japan (1,2). Early-stage endometrial
carcinoma shows a good prognosis, and the 5-y survival
rate is reported to be more than 90% in patients with stage
Ia or Ib determined by the International Federation of
Gynecology and Obstetrics (FIGO) classifications (3–5).
On the other hand, patients with advanced disease have a
significantly worse survival. Up to 20% of those with
endometrial carcinoma relapse and eventually die of their
disease. Previous studies suggested that the most important
prognostic factors in endometrial carcinoma were the
surgical FIGO stage, myometrial invasion, histologic type,
and differentiation grade (6–10). A noninvasive diagnostic
method to evaluate tumor aggressiveness and pathologic
features would be useful for deciding the therapeutic
strategy and predicting prognosis in patients with endome-
trial carcinoma.
We previously reported that estrogen receptor (ER)
expression coupled with glucose metabolism using
16a-18F-fluoro-17b-estradiol (FES) and 18F-FDG PET is
useful for the differential diagnosis of benign and malig-
nant uterine tumors (11). ER expression and glucose me-
tabolism of uterine tumors showed opposite tendencies
(i.e., high glucose metabolism and low ER expression in
malignant tumors and low glucose metabolism and high ER
expression in benign tumors). The purpose of the present
study was to investigate whether regional accumulation of
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18F-FES and 18F-FDG and the uptake ratio of 18F-FDG to
18F-FES correlate with the aggressiveness of endometrial
tumors in terms of stage and pathologic findings.
MATERIALS AND METHODS
Patients
Thirty-one patients (mean age, 56.06 15.3 y) with endometrial
thickening or suspected malignant tumors at cytologic analysis,
ultrasonography, or MRI participated in this study. None of the
patients received any biopsy or treatment before PET and MRI
studies. Definitive diagnosis was determined by postoperative
histopathologic analysis (n 5 25) or whole-endometrium curet-
tage (n 5 6). Final diagnoses were endometrial adenocarcinoma
(n5 22) and hyperplasia (n5 9) (Table 1). All 6 cases determined
by whole-endometrium curettage were endometrial hyperplasia. In
surgically staged patients, the final stage and grade were decided
by findings at hysterectomy. The staging, histology, and grading
criteria were based on the 1988 FIGO staging classification (3).
The results for 9 patients with endometrial carcinoma and 4
patients with hyperplasia were previously reported in our recent
study (11). This study was approved by the institutional review
board of the University of Fukui Hospital. Written informed
consent was obtained from all patients studied.
PET Procedures
All patients underwent preoperative PET scans with 18F-FES
and 18F-FDG to compare differences in tracer accumulation. Two
scans were obtained on 2 separate days within 1 wk in random
sequence. We used a whole-body tomograph (Advance; GE
Healthcare) that permits the simultaneous acquisition of 35 image
slices in a 2-dimensional acquisition mode, with interslice spacing
of 4.25 mm. Performance tests showed the intrinsic resolution of
the scanner to be 4.0–5.3 mm in the axial direction and 4.6–5.7
mm in the transaxial direction.
18F-FES was synthesized using a method reported elsewhere
(12,13). The specific activity was 100–200 GBq/mmol, and
radiochemical purity was greater than 99%. For each 18F-FES
and 18F-FDG PET study, approximately 185 MBq of tracer were
administered via the antecubital vein. Before the tracer adminis-
tration of each study, patients fasted at least 4 h to avoid elevation
of blood sugar levels in 18F-FDG PET and to reduce tracer
excretion to the intestines in 18F-FES PET. Fifty minutes after
the tracer injection, the patient was positioned supine in the PET
scanner, and a 16-min emission scan was started, with 3-min scans
at the pelvic region (2 bed positions) and 2-min scans in each
remaining region (5 bed positions) to completely cover the head to
inguinal regions. Postinjection transmission scans of 2 min at the
pelvis and 1 min in other areas were obtained after the emission
scans using a 68Ge/68Ga rod source for attenuation correction. The
PET data were reconstructed by the iterative method, with selec-
tion of 14 subsets and 2 iterations. The reconstructed images were
then converted to a semiquantitative image corrected by the
injection dose and the patient’s body weight (standardized uptake
value [SUV]) for data analysis.
MRI Scans and SUV Measurements
All patients underwent MRI during the time between the 2 PET
examinations, or within 1 wk from them, for diagnosis and to
obtain anatomic information about the pelvic organs. T1- and T2-
weighted images in the axial, sagittal, and coronal planes were
acquired with a 1.5-T superconducting MRI system (Signa; GE
Healthcare). The repetition and echo times for T1- and T2-
weighted images were 533 and 8 ms and 4,700 and 90 ms,
respectively. Contrast-enhanced MRI was performed with or
without fat saturation in the axial and sagittal planes after the
injection of gadolinium diethylenetriamine pentaacetic acid (0.1
mmol/kg). Staging of the tumors based on MRI findings was
performed by board-certified radiologists as follows: intact junc-
tional zone on T2-weighted MR images and superficial myome-
trial invasion (no more than half) on T2- and contrast T1-weighted
images were regarded as early stages and deep myometrial
invasion (more than half), cervical involvement, and pelvic lym-
phadenopathy as advanced stages.
Circular regions of interest (ROIs) with a fixed size of 8 mm in
diameter were drawn on the lesions to obtain the local SUV.
Individual MR images were referenced for placement of ROIs in
the appropriate region after PET and MR images were coregis-
tered (Body Guide; Advance Biologic Co.). ROIs were placed on
the resliced MRI sections after coregistration of 3 images in each
patient and the same ROIs were applied to the 18F-FES and 18F-
FDG PET images. Sagittal or coronal planes (2 or 3) of 6-mm
thickness were used to obtain SUV at the center of the lesion. A
single section at the center of the lesion was used when the lesion
was small and substantial partial-volume effects on the mean SUV
were expected. SUVs for each patient were averaged in 18F-FDG
and 18F-FES PET images. The mean SUV ratio of 18F-FDG to 18F-
FES for each lesion was also calculated.
Data Analysis
All patients were divided into 3 groups. The first group was
high-risk endometrial carcinoma with FIGO stage higher than Ib
TABLE 1. Patient Characteristics
Characteristic Value
Total patients (n) 31
Mean age (y) 56 6 15
Age range (y) 30–84
Menopausal status (n)
Premenopausal 13
Postmenopausal 18
Histopathologic type (n)
Endometrial adenocarcinoma 22
Endometrial hyperplasia 9
Stage of carcinoma (n)
Ia or Ib 14
Ic 3
II 2
III 3
Differentiation grade (n)
G1 12
G2 9
G3 1
Tumor size (n)
,1 cm 14
1–2 cm 8
2 cm , 9
High-risk carcinoma (n) 11
Low-risk carcinoma (n) 11
Carcinoma of stage Ib or lower with grade G2 or G3 was
included in high-risk group.
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or histologic grade higher than grade 1. The second group was
low-risk carcinoma with FIGO stage Ib or Ia and histologic grade
1. The third group was endometrial hyperplasia. SUVs for 18F-
FDG and 18F-FES and the 18F-FDG–to–18F-FES ratio were
compared among the 3 groups by 1-way ANOVA with a post
hoc Games–Howell test, which has robustness for analysis even in
unequal variance. Differences in tracer accumulation were also
compared between the 2 tracers using a paired t test. Statistical
analysis was performed using a software package (SPSS for
Microsoft Windows, version 11.5.1 J; SPSS Inc.).
Receiver-operating-characteristic (ROC) analysis was per-
formed to determine diagnostic accuracy and the optimal cutoff
value to differentiate high- versus low-risk groups and low-risk
versus hyperplasia groups using MedCalc (version 7.6.0.0; Med-
Calc Software). The area under the ROC curve (AUC) provided a
measure for the accuracy of a diagnostic test by PET parameters.
The diagnostic accuracy of MRI, compared with postoperative
definitive diagnosis, was evaluated by an ability to distinguish
carcinoma in advanced stages (FIGO stage $ Ic) from early stages
(FIGO stage # Ib) irrespective of histologic grade. The accuracy
of MRI findings and PET parameters was also compared using the
McNemar test. A probability value of less than 0.05 was consid-
ered to indicate a significant difference.
RESULTS
SUVs and Ratio
Table 1 summarizes patient characteristics including
tumor stage and lesion size. Thirteen patients were pre-
menopausal and 18 were postmenopausal. The mean SUVs
and 18F-FDG–to–18F-FES ratios for each group are given in
Table 2. Patients with high-risk endometrial carcinoma
showed a significantly higher accumulation of 18F-FDG
than 18F-FES (P , 0.0001, paired t test), whereas patients
with low-risk carcinoma did not show a significant differ-
ence between 18F-FDG and 18F-FES uptake. In contrast,
endometrial hyperplasia showed a significantly higher up-
take for 18F-FES than 18F-FDG (P , 0.005) in the primary
tumors. Figure 1 shows the tendencies toward an increase
in 18F-FDG uptake and a decrease in 18F-FES as disease
progressed to a higher stage or histologic grade. 18F-FDG
accumulation was not significantly different between high-
risk and low-risk endometrial carcinoma, although hyper-
plasia showed significantly lower 18F-FDG accumulation
than did high-risk (P , 0.0001) and low-risk (P , 0.005)
carcinoma. 18F-FES PET showed a significant difference
between these 2 groups of carcinoma (P , 0.05). In Figure
2, high-risk carcinoma showed a significantly greater 18F-
FDG–to–18F-FES ratio than did low-risk carcinoma (P ,
0.01) and endometrial hyperplasia (P , 0.005). Low-risk
carcinoma also showed a significantly higher 18F-FDG–
to–18F-FES ratio than hyperplasia (P , 0.0001).
ROC Analysis and Comparison with MRI
AUCs obtained from ROC analysis for distinction of
high- and low-risk carcinoma were 0.90, 0.81, and 0.72 for
the 18F-FDG–to–18F-FES ratio, 18F-FES SUV, and 18F-FDG
SUV, respectively, indicating that the 18F-FDG–to–18F-FES
ratio is the most informative index for differentiating ag-
gressiveness of carcinoma although no significant differ-
ence was observed in AUCs by the z test. Table 3 shows the
diagnostic accuracy for the 3 PET parameters and MRI
findings for distinction of high-risk from low-risk carci-
noma. ROC analysis determined the optimal cutoff value for
each PET parameter to distinguish high- and low-risk
carcinoma. The optimal 18F-FDG–to–18F-FES cutoff ratio
of 2.0 provided 73% sensitivity and 100% specificity, which
yielded the greatest accuracy of 86% among all PET
parameters and MRI. Because all lesions of endometrial
hyperplasia showed a low 18F-FDG–to–18F-FES ratio of
less than 0.5, a cutoff ratio of 0.5 could distinguish all cases
of low-risk carcinoma from hyperplasia correctly, yielding
no false-positive findings and 100% accuracy. A cutoff 18F-
FDG SUVof 2.0 also differentiated malignant tumors from
benign lesions (Fig. 1). The accuracies of PET parameters
and MRI findings were statistically compared, and a sig-
nificant difference was observed between the 18F-FDG–
to–18F-FES ratio and 18F-FDG SUV (P, 0.005, McNemar
test).
Representative Cases
Representative images of each group are given in Figures
3–5. Figure 3 shows high-risk endometrial carcinoma
(FIGO stage Ic, histologic grade 2). MRI findings suggested
no myometrial invasion (stage Ia), and PET images showed
high 18F-FDG and moderate 18F-FES accumulation in the
primary tumor, with an 18F-FDG–to–18F-FES ratio of 2.5,
indicating high-risk carcinoma. Figure 4 is a case of low-
risk endometrial carcinoma (FIGO stage Ib, histologic
grade 1) showing high 18F-FDG and 18F-FES uptake with
an 18F-FDG–to–18F-FES ratio of 1.3. MRI also indicated
early-stage endometrial carcinoma with superficial myo-
TABLE 2. Regional SUVs and 18F-FDG–to–18F-FES SUV Ratio
Class Patients 18F-FDG SUV 18F-FES SUV 18F-FDG–to–18F-FES ratio
High-risk carcinoma (stage $ Ic or grade $ 2) 11 9.9 6 2.6* (5.4–14.8) 3.4 6 1.6 (1.3–6.3) 3.6 6 2.1 (1.3–7.4)
Low-risk carcinoma (stage # Ib and grade 1) 11 7.1 6 3.7 (2.4–12.5) 5.3 6 1.8 (2.1–8.1) 1.3 6 0.5 (0.5–1.8)
Endometrial hyperplasia 9 1.5 6 0.3 (1.1–1.9) 5.6 6 2.4y (2.7–11.0) 0.3 6 0.1 (0.2–0.4)
*P , 0.0001.
yP , 0.005 significantly higher between the 2 PET tracers (paired t test).
Values are mean 6 SD. Statistical significance for group comparison is given in Figures 1 and 2. Data in parentheses are ranges.
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metrial invasion (Ib). Endometrial hyperplasia had a high
level of 18F-FES accumulation corresponding to the thick-
ening of endometrium on MRI (Fig. 5). The 18F-FDG–
to–18F-FES ratio of this patient was 0.2.
DISCUSSION
Our recent PET study using 18F-FES and 18F-FDG
revealed that uterine tumors had opposite tendencies in
terms of 18F-FES and 18F-FDG accumulation, which rep-
resents ER expression and glucose metabolism, between
benign and malignant lesions (11). Thus, PET studies with
the 2 tracers were useful to provide pathophysiologic
information for the differential diagnosis of uterine tumors.
In the present study with a larger sample size of endome-
trial tumors, 2 PET images could distinguish endometrial
carcinoma from benign lesions with PET parameters of 18F-
FDG SUV and 18F-FDG–to–18F-FES ratio. Furthermore,
the regional 18F-FDG–to–18F-FES ratio and the 18F-FES
SUV could distinguish high-risk carcinoma (FIGO stage $
Ic or histologic grade $ 2) from low-risk carcinoma (FIGO
stage # Ib and histologic grade 1). This index provided the
information that endometrial carcinoma with an advanced
stage or a higher grade reduces estrogen dependency with
an increase in glucose metabolism. In contrast, endometrial
hyperplasia showed a significantly low 18F-FDG–to–18F-
FES ratio of less than 0.5, indicating its preserved ER
expression without an increase in glucose consumption.
Low-risk carcinoma with moderate-to-intense 18F-FDG and
18F-FES accumulation is considered between high-risk
carcinoma and hyperplasia in terms of aggressiveness.
Several reports indicated that 18F-FDG PET is useful for
managing pre- and postoperative patients with endometrial
carcinoma mainly by detecting lymph node metastasis
(14–17). The classification of tumor characteristics deter-
mined by 18F-FDG uptake and the 18F-FDG–to–18F-FES
ratio could play an important role in the differential
diagnosis of endometrial lesions and in deciding the ther-
apeutic strategy. The cutoff 18F-FDG–to–18F-FES ratio of
0.5 and the 18F-FDG SUV of 2.0 could differentiate low-
risk carcinoma from hyperplasia, and all malignancies were
correctly distinguished from benign lesions, with no false-
positive findings and 100% accuracy. Some characteristic
MRI findings of benign endometrial lesions such as endo-
metrial hyperplasia and polyps were reported previously
(18,19). Those specific findings are occasionally detected in
the case of relatively large tumor volume, whereas it is dif-
ficult to differentiate small-sized endometrial hyperplasia
from stage Ia carcinoma. PET, which characterizes tumor
biofunction, would be more reliable than MRI findings for
the preoperative diagnosis. Uterine tumors with estrogen-
dependent function such as endometrial carcinoma may lose
their estrogen-dependent function, reduce ER expression,
and increase glucose metabolism because of aberrant gly-
colysis with dedifferentiation. This functional transforma-
tion could have shown opposite tendencies of high glucose
metabolism and low 18F-FES accumulation in malignant
FIGURE 1. Box-and-whisker plots of uptake of each tracer
among 3 groups. Horizontal bars inside boxes indicate
median values. Error bars indicate farthest points that are
not outliers. Significant differences in 18F-FDG accumulation
were observed between hyperplasia and high-risk (P ,
0.0001) or low-risk (P , 0.005) endometrial carcinoma. 18F-
FDG accumulation was not significantly different between
high-risk and low-risk carcinoma, although 18F-FES PET
showed significant difference between these 2 groups (P ,
0.05). High-R 5 high-risk carcinoma; low-R 5 low-risk
carcinoma; NS 5 not significant.
FIGURE 2. Box-and-whisker plots of 18F-FDG–to–18F-FES
SUV ratio among 3 groups. Significant differences were
observed between high-risk and low-risk carcinoma (P ,
0.01), between high-risk carcinoma and hyperplasia (P ,
0.005), and between low-risk carcinoma and hyperplasia
(P , 0.0001). High-R 5 high-risk carcinoma; low-R 5 low-
risk carcinoma.
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tumors, especially in high-risk carcinoma. This noninvasive
method could avoid unnecessary operations or invasive
whole-endometrium curettage, which is important for pre-
serving women’s reproductive potential.
Functional PET is considered a promising method for
deciding on personalized treatment. Although it would be
difficult to determine the histologic grade of endometrial
lesions by pelvic MRI, PET scans with 18F-FES and 18F-
FDG can reflect tumor aggressiveness (invasiveness and
grade) using the index of 18F-FDG–to–18F-FES ratio. As
shown in the present study, the diagnostic accuracy of the
18F-FDG–to–18F-FES ratio was better than that of MRI in
distinguishing high-risk from low-risk carcinoma. Surgical
pathologic staging is now the standard of care for endome-
trial carcinoma (3). However, the role of comprehensive
surgical staging, especially pelvic and paraaortic lymphad-
enectomy for all patients, remains controversial. Several
reports asserted that patients with low-risk endometrial
carcinoma can be treated with hysterectomy only (20,21).
Avoiding lymphadenectomy decreases complications after
surgery. Patients with low-risk endometrial carcinoma de-
termined by an 18F-FDG–to–18F-FES ratio of less than 2.0
may be able to avoid pelvic or paraaortic lymphadenec-
tomy, although the cutoff values for PET parameters should
be validated prospectively using an independent patient
group in further study because the cutoffs were optimized
from this particular dataset. To decrease unnecessary lym-
phadenectomy and establish a noninvasive evaluation
method for risk management in patients with endometrial
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FIGURE 3. T2-weighted (A), contrast-enhanced
T1-weighted MR (B), 18F-FDG (C), and 18F-FES PET (D)
images of 60-y-old woman with endometrial carcinoma
(arrows). PET images showed intense 18F-FDG uptake (SUV,
11.6) and moderate 18F-FES uptake (SUV, 4.7) in tumor.
Preoperative staging by MRI suggested no myometrial
invasion, whereas PET findings with an 18F-FDG–to–18F-
FES ratio of 2.5 indicated high-risk carcinoma. Postopera-
tive histopathologic result was high-risk carcinoma with
FIGO stage Ic and histologic grade 2.
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carcinoma, further PET studies with a larger patient sample
and a long-term follow-up would be needed.
The present study included 2 patients with paraaortic and
pelvic lymph node metastases (stage IIIc) among 11
patients high-risk carcinomas. All metastatic lymph nodes
were detected correctly by 18F-FDG PET, whereas the
lymph nodes could not be identified with MRI in one of the
patients. Although MRI findings are superior to 18F-FDG
PET parameters in terms of the regional discrimination of
carcinoma in stage Ia or Ib from stage Ic (or higher),
18F-FDG PET is considered to show a higher detection rate
than MRI for distant metastasis. In addition, histopatho-
logic results of the cases with lymph node metastases were
grades 2 and 3, in which the primary sites showed far
higher 18F-FDG–to–18F-FES ratios (4.3 and 7.1, respec-
tively) than the cutoff value. These results indicate that PET
studies with 18F-FDG and 18F-FES will reflect tumor
aggressiveness, which is useful information for the treat-
ment of patients with endometrial lesions.
Although simple stage differentiation with PET param-
eters was also evaluated by ROC analysis, this method
could not differentiate early stages from advanced stages
because stage Ia or Ib carcinoma with grades 2 or 3 showed
a tracer uptake tendency similar to that of the high-risk
group. Thus, we did not use this simple classification in the
present study. The differentiation of high- and low-risk
tumors as determined here would be more appropriate for
the evaluation of tumor aggressiveness.
CONCLUSION
Endometrial carcinoma reduces estrogen dependency
with increased glucose metabolism as it progresses to a
higher stage or grade. The 18F-FDG–to–18F-FES ratio
calculated from 18F-FES and 18F-FDG PET is the most
informative index reflecting tumor aggressiveness. This
index will be useful for noninvasive diagnosis and for
deciding on the appropriate therapeutic strategy for patients
with endometrial carcinoma.
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